Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H11NO3 |
Molecular Weight | 181.1885 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC(=O)C1=CC(O)=C(O)C=C1
InChI
InChIKey=PZMVOUYYNKPMSI-UHFFFAOYSA-N
InChI=1S/C9H11NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,10-12H,5H2,1H3
Adrenalone is a keton form of the natural substrate epinephrine. Adrenalone is evidently formed in vivo by hydrolytic cleavage of the diester by esterases. It is an adrenergic receptor agonist. Adrenalone inhibits the norepinephrine synthesis and dopamine beta oxidase. It is known to have very weak sympathomimetic activity when compared to adrenaline. Adrenalone has the high radioprotective effect. It is a topical nasal decongestant. Adrenalone has hemostatic, sympathomimetic and vasoconstrictor therapeutic functions.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3102 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13899905 |
|||
Target ID: Norepinephrine synthesis Sources: https://www.ncbi.nlm.nih.gov/pubmed/13899911 |
|||
Target ID: CHEMBL2095203 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Stryphnon Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Electron spin resonance-spin stabilization of semiquinones produced during oxidation of epinephrine and its analogues. | 1984 Jan 10 |
|
Formation of adrenaline in the iris-ciliary body from adrenalone diesters. | 1984 Jun |
|
Modified syntheses of dopamine-4-sulfate, epinephrine-3-sulfate, and norepinephrine-3-sulfate: determination of the position of the sulfate group by 1H-NMR spectroscopy. | 1988 Aug |
|
[Radiation protective effect of beta-ketoanalogs of hydroxyphenyl ethanolamines]. | 1997 Nov-Dec |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9467647
Mice: 50-150 mumol/kg
Route of Administration:
Unknown
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21885739
Substrate uptake by norepinephrine transporter was reduced to 99% (27%) at 10-uM (100-uM) concentrations of adrenalone; the half maximal inhibitory concentration (IC50) value of adrenalone was 36.9 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A01AD06
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
||
|
WHO-ATC |
B02BC05
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
||
|
WHO-VATC |
QB02BC05
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
||
|
WHO-VATC |
QA01AD06
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
||
|
NCI_THESAURUS |
C87053
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB05279MIG
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
7436
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
99-45-6
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
DTXSID5048710
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
17073
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | RxNorm | ||
|
EGU41QL329
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
m1430
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
Adrenalone
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103996
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
DB13394
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
100000087688
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
243611
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
3174
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
C81339
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
202-756-9
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
96
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY | |||
|
C040224
Created by
admin on Fri Dec 15 16:10:50 GMT 2023 , Edited by admin on Fri Dec 15 16:10:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)